93. Primary biliary cholangitis
230 clinical trials,   215 drugs   (DrugBank: 51 drugs),   34 drug target genes,   107 drug target pathways
Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04047160 (ClinicalTrials.gov) | August 29, 2019 | 30/7/2019 | Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) | An Open-Label, Dose-Finding Study for the CBP / ß-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I) | Primary Biliary Cholangitis (PBC);Liver Cirrhosis, Biliary | Drug: OP-724 | Kiminori Kimura, MD | OHARA Pharmaceutical Co., Ltd.;Japan Agency for Medical Research and Development | Recruiting | 20 Years | 74 Years | All | 12 | Phase 1 | Japan |